Iguratimod combined with tofacitinib in rheumatoid arthritis patients with inadequate response to conventional synthetic or biological DMARDs: a retrospective study

Weijuan Wang, Jie Chang

Open source

DOI
10.1007/s10067-026-08497-x
Published
2026-10-27
Container
Clinical Rheumatology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10067-026-08497-x,
  title = {Iguratimod combined with tofacitinib in rheumatoid arthritis patients with inadequate response to conventional synthetic or biological DMARDs: a retrospective study},
  author = {Weijuan Wang and Jie Chang},
  year = {2026},
  journal = {Clinical Rheumatology},
  doi = {10.1007/s10067-026-08497-x},
  url = {https://doi.org/10.1007/s10067-026-08497-x}
}

RIS

TY  - JOUR
TI  - Iguratimod combined with tofacitinib in rheumatoid arthritis patients with inadequate response to conventional synthetic or biological DMARDs: a retrospective study
AU  - Weijuan Wang
AU  - Jie Chang
PY  - 2026
JO  - Clinical Rheumatology
DO  - 10.1007/s10067-026-08497-x
UR  - https://doi.org/10.1007/s10067-026-08497-x
ER  - 

APA

Wang, W., & Chang, J. (2026). Iguratimod combined with tofacitinib in rheumatoid arthritis patients with inadequate response to conventional synthetic or biological DMARDs: a retrospective study. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08497-x

Source records